CEO Bilotto buys 20,000 DHC shares at $4.89; holds 266,284 shares post-transaction amid -$164.0M net income
President and CEO Christopher J. Bilotto purchased 20,000 shares at $4.89 on 2025-12-15, increasing his holdings by 8.1% to 266,284 shares total. This open-market purchase occurred while the company reported negative net income of $-164.0M despite quarterly revenue of $388.7M, signaling structural profitability challenges. The stock has recovered 9.3% over the past 90 days and is currently trading at $4.82, only 2.4% below its 52-week high of $4.94. The insider's accumulation during a period of significant financial losses—while the company simultaneously carries a market capitalization of $1.2B—presents a mixed signal requiring closer examination of whether this reflects conviction in a turnaround or other considerations.
CFO Matthew C. Brown buys 2,000 shares of DHC at $2.55 amid -30.8% 30-day decline; company unprofitable.
Matthew C. Brown, CFO and Treasurer, purchased 2,000 shares at $2.55 on 2024-11-13, a deliberate acquisition that increased his holdings from 84,282 to 86,282 shares. The timing occurs against significant headwinds: the stock has declined 30.8% over the past 30 days and trades 41.0% below its 52-week high of $4.19. Most importantly, the company's fundamentals show the organization is unprofitable, with a net loss of $-98.7M in its most recent full fiscal year despite quarterly revenue of $373.6M. The purchase by a senior financial officer during a period of deteriorating price action and company-wide losses presents a fact pattern that warrants investor attention to both the company's near-term operational trajectory and the CFO's rationale for capital allocation.
Add DHC to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.
